Author

C. W. McNamara

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Discovery and Optimization of Imidazothiazole Carboxamides as Novel Anti-Tuberculosis Agents

Screening of the open-access CRESTdb small-molecule library identified the imidazothiazole carboxamide sCQG200 (1) as an initial hit, with activity against H37Rv and Erdman Mycobacterium tuberculosis strains in cholesterol-containing medium (MIC90= 6.88 µM and 4.48 µM, respectively) and against intracellular Mtb (EC50=...

Leo Meng, David Grant, Han Xie et al. · bioRxiv · 0 citations

Open access Sep 2026

Discovery and Structure–Activity Relationship Optimization of a Novel Rv1625c Agonist Chemotype with Antitubercular Activity

Rv1625c/Cya has emerged as a promising target for the development of treatment-shortening therapies for tuberculosis. Screening of an Enamine compound library identified sBQQ004 as an initial hit, and rapid hit optimization led to compound 1, which was subsequently confirmed as an Rv1625c/Cya agonist. Structure–activit...

Han Xie, Paridhi Sukheja, Kirsten T. Tolentino et al. · bioRxiv · 0 citations

Open access Oct 2026

Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990

COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (Mpro) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, an...

N. G. R. Dayan Elshan, Karen C. Wolff, L. Riva et al. · bioRxiv · 0 citations